It is now official. The short report is a poorly researched piece. Mindray continues to be a reliable grower.
Ottoman's baying at our heels again today= 5% drop.
Once again they do regurgitate
their baseless claims so full of hate.
With a laundry list of more the same
but still provide no author’s name.
You have to ask but doubt they’ll tell
at what price these shorts did choose to sell?
And as goes up the price of the stock.
How much these knaves go into hock?
As long as MR continues to perform from a revenue and profit perspective, there is not much this short-seller can do.
China is in the process of upgrading its entire healthcare system which serves 4 times the population of the USA. There are plenty of room still for MR to grow, just within China alone.